IRF9 and lung cancer: IRF9 is also a key regulator according to PAH GRN, along with other 21 TFs, and regulates 189 PAH common overregulated DEGs, including LINC01089, which are co-expressed in lung cancer models and are related to cell development and differentiation, regulation of cellular component size, and cytoplasmic vesicle membrane and retromer complex binding (Table S1.3).